Senolytic drug development — the targeted elimination of senescent cells (cells that have ceased dividing but resist apoptosis and secrete a pro-inflammatory senescence-associated secretory phenotype, SASP) using compounds including dasatinib plus quercetin, navitoclax, and ABT-263 representing the most scientifically advanced anti-ageing pharmacological approach, with the Anti Ageing Drugs Market increasingly defined by senolytics' potential to address multiple age-related conditions through a unified biological mechanism rather than disease-by-disease therapeutic approaches.

Scientific foundation of senolytic therapy — the discovery that senescent cell accumulation in aging tissues drives multiple age-related pathologies (osteoarthritis, pulmonary fibrosis, atherosclerosis, diabetes, neurodegeneration) through SASP's chronic sterile inflammation creating the biological rationale for senolytic clearance as a broadly beneficial intervention. Landmark Mayo Clinic studies (van Deursen, Kirkland groups) demonstrating that transgenic clearance of p16Ink4a-positive senescent cells extends healthy lifespan in mice by twenty-five percent and ameliorates multiple age-related diseases, establishing proof-of-concept for pharmacological senolytic approaches.

Clinical pipeline advancement — Unity Biotechnology's clinical programs (UBX0101 for knee osteoarthritis, UBX1325 for diabetic macular edema), Oisín Biotechnologies' senolytic gene therapy, and multiple academic clinical trials (Mayo Clinic's dasatinib-quercetin trials in idiopathic pulmonary fibrosis, diabetic kidney disease, and Alzheimer's disease) advancing senolytic therapy from preclinical proof-of-concept toward clinical validation. The dasatinib-quercetin combination's clinical use in idiopathic pulmonary fibrosis clinical trials demonstrating feasibility of senolytic administration in human subjects with measurable SASP biomarker reduction.

Natural compound senolytics — quercetin (flavonoid), fisetin (flavonoid with stronger preclinical data than quercetin), piperlongumine, navitoclax, and various plant polyphenols demonstrating senolytic activity in cell culture and animal models creating consumer market demand in the nutritional supplement sector ahead of pharmaceutical clinical validation. The supplement-to-pharmaceutical translation creating both commercial opportunity (early consumer adoption) and scientific challenge (distinguishing pharmaceutical-grade senolytic efficacy from supplement market claims).

Should senolytic drugs, if proven effective in clinical trials for age-related diseases, be approved under individual disease indications or should regulatory agencies consider creating a new "anti-ageing" or "geroscience" regulatory pathway recognizing biological aging itself as a treatable condition?

FAQ

What is the current clinical trial status of senolytic drugs and what results have been reported? Senolytic clinical trial landscape: dasatinib + quercetin (D+Q): Mayo Clinic IPF trial: Phase II, 3-day D+Q pulses every 3 weeks; results: improved physical function (6-minute walk test), reduced plasma SASP markers (MMP-3, MMP-12, IL-1α); Mayo Clinic diabetic kidney disease trial: reduced p16+ and p21+ kidney cells post-treatment; Mayo Clinic Alzheimer's disease trial (ALSENLITE): ongoing, biomarker results expected; Unity Biotechnology: UBX0101 (MDM2 inhibitor senolytic): Phase II knee OA — did not meet primary endpoint (pain reduction vs. placebo); UBX1325 (Bcl-xL inhibitor): diabetic macular edema Phase I: tolerable safety profile, exploratory efficacy signals; fisetin: University of Minnesota aging frailty trial: ongoing; navitoclax: being developed as combination for myelofibrosis (onco-indication); commercial compounds targeting senescence: Oisín Biotechnologies, Rejuvenate Bio (targeting SASP); academic programs: Buck Institute for Research on Aging, Salk Institute, Mayo Clinic — multiple investigator-initiated trials; limitations: lack of validated senescence biomarkers for patient selection and treatment monitoring remains key clinical development challenge.

What consumer anti-ageing supplements claim senolytic activity and how do they compare to pharmaceutical senolytics? Consumer senolytic supplement market: established compounds with preclinical senolytic data: quercetin (widely available, well-tolerated, weak senolytic in isolation); fisetin (stronger preclinical data than quercetin; Swanson Health, Life Extension, Thorne offering standardized extracts); piperlongumine (research compound, limited consumer products); EGCG (epigallocatechin gallate from green tea) — mild senolytic activity; navitoclax analogs — prescription cancer drug, not consumer-available; combination products: various 'senolytic blend' supplements combining quercetin, fisetin, and other flavonoids; pricing: INR 2,000–8,000 (USD 24–96) monthly for standardized fisetin/quercetin combinations; consumer market scale: multimillion dollar and growing as longevity interest increases; evidence gap: no clinical trial has demonstrated senolytic benefit from consumer-grade supplement dosing comparable to pharmaceutical-dose clinical trials; dose difference: clinical D+Q trials use dasatinib 100mg + quercetin 1,000mg intermittently (day 1 and 2 of 3-week cycle) — very different from typical 500mg daily quercetin supplement; regulatory note: supplements not evaluated by FDA for senolytic activity; pharmaceutical development required for validated therapeutic claims.

#AntiAgeingDrugsMarket #Senolytics #AntiAgeing #Longevity #CellularAgeing #HealthspanScience